370 related articles for article (PubMed ID: 24403854)
21. Inhibition of NAMPT aggravates high fat diet-induced hepatic steatosis in mice through regulating Sirt1/AMPKα/SREBP1 signaling pathway.
Wang LF; Wang XN; Huang CC; Hu L; Xiao YF; Guan XH; Qian YS; Deng KY; Xin HB
Lipids Health Dis; 2017 Apr; 16(1):82. PubMed ID: 28449683
[TBL] [Abstract][Full Text] [Related]
22. NAD metabolic dependency in cancer is shaped by gene amplification and enhancer remodelling.
Chowdhry S; Zanca C; Rajkumar U; Koga T; Diao Y; Raviram R; Liu F; Turner K; Yang H; Brunk E; Bi J; Furnari F; Bafna V; Ren B; Mischel PS
Nature; 2019 May; 569(7757):570-575. PubMed ID: 31019297
[TBL] [Abstract][Full Text] [Related]
23. Discovery and Characterization of Novel Nonsubstrate and Substrate NAMPT Inhibitors.
Wilsbacher JL; Cheng M; Cheng D; Trammell SAJ; Shi Y; Guo J; Koeniger SL; Kovar PJ; He Y; Selvaraju S; Heyman HR; Sorensen BK; Clark RF; Hansen TM; Longenecker KL; Raich D; Korepanova AV; Cepa S; Towne DL; Abraham VC; Tang H; Richardson PL; McLoughlin SM; Badagnani I; Curtin ML; Michaelides MR; Maag D; Buchanan FG; Chiang GG; Gao W; Rosenberg SH; Brenner C; Tse C
Mol Cancer Ther; 2017 Jul; 16(7):1236-1245. PubMed ID: 28468779
[TBL] [Abstract][Full Text] [Related]
24. Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibition.
Cea M; Cagnetta A; Fulciniti M; Tai YT; Hideshima T; Chauhan D; Roccaro A; Sacco A; Calimeri T; Cottini F; Jakubikova J; Kong SY; Patrone F; Nencioni A; Gobbi M; Richardson P; Munshi N; Anderson KC
Blood; 2012 Oct; 120(17):3519-29. PubMed ID: 22955917
[TBL] [Abstract][Full Text] [Related]
25. Targeting of NAD metabolism in pancreatic cancer cells: potential novel therapy for pancreatic tumors.
Chini CC; Guerrico AM; Nin V; Camacho-Pereira J; Escande C; Barbosa MT; Chini EN
Clin Cancer Res; 2014 Jan; 20(1):120-30. PubMed ID: 24025713
[TBL] [Abstract][Full Text] [Related]
26. Gut microbiota severely hampers the efficacy of NAD-lowering therapy in leukemia.
ElMokh O; Matsumoto S; Biniecka P; Bellotti A; Schaeuble K; Piacente F; Gallart-Ayala H; Ivanisevic J; Stamenkovic I; Nencioni A; Nahimana A; Duchosal MA
Cell Death Dis; 2022 Apr; 13(4):320. PubMed ID: 35396381
[TBL] [Abstract][Full Text] [Related]
27. Structural and biochemical analyses of the catalysis and potency impact of inhibitor phosphoribosylation by human nicotinamide phosphoribosyltransferase.
Oh A; Ho YC; Zak M; Liu Y; Chen X; Yuen PW; Zheng X; Liu Y; Dragovich PS; Wang W
Chembiochem; 2014 May; 15(8):1121-30. PubMed ID: 24797455
[TBL] [Abstract][Full Text] [Related]
28. Oleate ameliorates palmitate-induced reduction of NAMPT activity and NAD levels in primary human hepatocytes and hepatocarcinoma cells.
Penke M; Schuster S; Gorski T; Gebhardt R; Kiess W; Garten A
Lipids Health Dis; 2017 Oct; 16(1):191. PubMed ID: 28974242
[TBL] [Abstract][Full Text] [Related]
29. NAD
Moore AM; Zhou L; Cui J; Li L; Wu N; Yu A; Poddar S; Liang K; Abt ER; Kim S; Ghukasyan R; Khachatourian N; Pagano K; Elliott I; Dann AM; Riahi R; Le T; Dawson DW; Radu CG; Donahue TR
Proc Natl Acad Sci U S A; 2021 Feb; 118(8):. PubMed ID: 33597293
[TBL] [Abstract][Full Text] [Related]
30. Nicotinamide phosphoribosyltransferase promotes epithelial-to-mesenchymal transition as a soluble factor independent of its enzymatic activity.
Soncini D; Caffa I; Zoppoli G; Cea M; Cagnetta A; Passalacqua M; Mastracci L; Boero S; Montecucco F; Sociali G; Lasigliè D; Damonte P; Grozio A; Mannino E; Poggi A; D'Agostino VG; Monacelli F; Provenzani A; Odetti P; Ballestrero A; Bruzzone S; Nencioni A
J Biol Chem; 2014 Dec; 289(49):34189-204. PubMed ID: 25331943
[TBL] [Abstract][Full Text] [Related]
31. Identification of novel resistance mechanisms to NAMPT inhibition via the de novo NAD
Guo J; Lam LT; Longenecker KL; Bui MH; Idler KB; Glaser KB; Wilsbacher JL; Tse C; Pappano WN; Huang TH
Biochem Biophys Res Commun; 2017 Sep; 491(3):681-686. PubMed ID: 28756225
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of Nicotinamide Phosphoribosyltransferase (NAMPT), an Enzyme Essential for NAD+ Biosynthesis, Leads to Altered Carbohydrate Metabolism in Cancer Cells.
Tan B; Dong S; Shepard RL; Kays L; Roth KD; Geeganage S; Kuo MS; Zhao G
J Biol Chem; 2015 Jun; 290(25):15812-15824. PubMed ID: 25944913
[TBL] [Abstract][Full Text] [Related]
33. Effect of Phosphoribosyltransferase Down-regulation on Malignant Glioma Cell Characteristics.
Kamada M; Ikeda K; Manome Y
Anticancer Res; 2020 Sep; 40(9):4895-4905. PubMed ID: 32878777
[TBL] [Abstract][Full Text] [Related]
34.
Lucena-Cacace A; Otero-Albiol D; Jiménez-García MP; Muñoz-Galvan S; Carnero A
Clin Cancer Res; 2018 Mar; 24(5):1202-1215. PubMed ID: 29203587
[No Abstract] [Full Text] [Related]
35. NAMPT suppresses glucose deprivation-induced oxidative stress by increasing NADPH levels in breast cancer.
Hong SM; Park CW; Kim SW; Nam YJ; Yu JH; Shin JH; Yun CH; Im SH; Kim KT; Sung YC; Choi KY
Oncogene; 2016 Jul; 35(27):3544-54. PubMed ID: 26568303
[TBL] [Abstract][Full Text] [Related]
36. Mechanism of Allosteric Modulation of Nicotinamide Phosphoribosyltransferase to Elevate Cellular NAD
Ratia KM; Shen Z; Gordon-Blake J; Lee H; Laham MS; Krider IS; Christie N; Ackerman-Berrier M; Penton C; Knowles NG; Musku SR; Fu J; Velma GR; Xiong R; Thatcher GRJ
Biochemistry; 2023 Feb; 62(4):923-933. PubMed ID: 36746631
[TBL] [Abstract][Full Text] [Related]
37. Target enzyme mutations are the molecular basis for resistance towards pharmacological inhibition of nicotinamide phosphoribosyltransferase.
Olesen UH; Petersen JG; Garten A; Kiess W; Yoshino J; Imai S; Christensen MK; Fristrup P; Thougaard AV; Björkling F; Jensen PB; Nielsen SJ; Sehested M
BMC Cancer; 2010 Dec; 10():677. PubMed ID: 21144000
[TBL] [Abstract][Full Text] [Related]
38. Nicotinamide phosphoribosyltransferase can affect metastatic activity and cell adhesive functions by regulating integrins in breast cancer.
Santidrian AF; LeBoeuf SE; Wold ED; Ritland M; Forsyth JS; Felding BH
DNA Repair (Amst); 2014 Nov; 23():79-87. PubMed ID: 25263164
[TBL] [Abstract][Full Text] [Related]
39. Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma.
Heske CM; Davis MI; Baumgart JT; Wilson K; Gormally MV; Chen L; Zhang X; Ceribelli M; Duveau DY; Guha R; Ferrer M; Arnaldez FI; Ji J; Tran HL; Zhang Y; Mendoza A; Helman LJ; Thomas CJ
Clin Cancer Res; 2017 Dec; 23(23):7301-7311. PubMed ID: 28899971
[No Abstract] [Full Text] [Related]
40. Preclinical assessment of the ADME, efficacy and drug-drug interaction potential of a novel NAMPT inhibitor.
Liederer BM; Cheong J; Chou KJ; Dragovich PS; Le H; Liang X; Ly J; Mukadam S; Oeh J; Sampath D; Wang L; Wong S
Xenobiotica; 2019 Sep; 49(9):1063-1077. PubMed ID: 30257601
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
